Telodine Tablet (Tolterodine L-Tartrate)

Adult dose

Adults: Administer 2 mg of tolterodine L-tartrate orally twice daily. However, based on the patient's response and tolerability, the dose may be reduced from 2 mg to 1 mg per dose and administered twice daily. Patients with renal impairment, hepatic impairment, or taking ketoconazole or other potent CYP3A4 inhibitors: A dose of 1 mg of this medicine twice daily is recommended.

This medication should not be used in patients with urinary retention or slow gastrointestinal motility. It should also be avoided in patients with uncontrolled angle-closure glaucoma, severe myasthenia gravis, or severe ulcerative colitis. Patients with allergies to this medication or its components should not take it. This medication should be used with caution in patients at risk of urinary obstruction or those with angle-closure glaucoma, gastrointestinal obstruction disease, or impaired kidney or liver function. Caution is also needed when used in combination with certain antibiotics, antifungals, immunosuppressants, and in patients at risk of autonomic neuropathy or reduced gastrointestinal motility. Common side effects may include dry mouth, dyspepsia, and reduced tear production. Other reported side effects include headaches, dizziness, drowsiness, constipation, urinary difficulty, dry skin, and allergic reactions. Serious side effects, although rare, may include heart rhythm disturbances, hallucinations, and memory impairment, so any unusual symptoms should be discussed with a physician immediately. This medication can affect heart rhythm, so patients with prolonged QT interval or those taking certain antiarrhythmic drugs should use it cautiously. Patients with electrolyte imbalances or bradycardia should also be careful when using this medication. This medication may impair the ability to drive or operate machinery, so caution is advised during use. Pregnant or nursing women are advised against using this medication, and women of childbearing age should use appropriate contraception. Safety in children has not been established, so it is principle not to use it in pediatric patients. In cases of overdose, severe visual disturbances, urinary difficulties, hallucinations, and convulsions may occur, requiring immediate hospital treatment for appropriate care. This medication should be stored out of reach of children and not transferred to other containers for safety.

• Dry mouth
• dyspepsia
• reduced tear production
• bronchitis
• allergic reactions
• confusion
• drowsiness
• dizziness
• headache
• neurosensitivity

This medication should be stored in a tightly sealed container to prevent contact with air, preferably at a cool room temperature below 25 degrees Celsius. Maintaining this storage condition will help preserve the medication's effectiveness and prevent degradation.

Appearance

White, biconvex, round film-coated tablet

Package unit

30 tablets (10 tablets/ PTP x 3)